Detalles de la búsqueda
1.
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Diabetes Obes Metab
; 25(3): 832-843, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36478142
2.
Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.
Metabolism
; 143: 155550, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36958671
3.
Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days.
Exp Clin Endocrinol Diabetes
; 130(12): 773-782, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36343645
4.
Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity.
Clin Diabetes Endocrinol
; 7(1): 16, 2021 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34391480
Resultados
1 -
4
de 4
1
Próxima >
>>